Literature DB >> 3815265

Angiosarcoma of the face and scalp, prognosis and treatment.

C A Holden, M F Spittle, E W Jones.   

Abstract

72 patients with angiosarcoma (AS) of the face and scalp have been analyzed with respect of various prognostic factors and the effects of different treatment regimes. This disease predominantly occurs in the elderly (age range, 56-92 years), and affects men rather more frequently than women (men: 44, women: 28). The clinical presentation varied, and included bruise-like lesions, dusky plaques, chronic edema or cellulitis, ulcerated nodules, pyoderma, and infected conditions. Due to lack of clinical awareness and problems with histologic assessment, delays in diagnosis were frequent. The majority of the tumors arose in the upper part of the face or scalp. Less commonly, the central part of the face was affected while only three tumors developed in the mandibular region. Overall the prognosis was poor; one half of the patients died within 15 months of presentation. Only 12% of the patients survived 5 years or more. Patients with lesions that were less than 10 cm in diameter responded better to treatment and statistically survived longer than those with larger lesions, emphasizing the crucial importance of early diagnosis. There is some indication that men, younger patients, patients with lesions on the central part of the face survived longer, but this was not of statistical significance. The histologic differentiation of the tumors at presentation also was of doubtful prognostic significance. Despite the overall poor prognosis, radical radiotherapy (mostly wide-field electron-beam therapy) in seven patients resulted in the apparent eradication of the local skin disease and prolonged survival of the patients. Pulmonary metastases developed 10 years later in two of those patients, however, but the face and scalp remained tumor-free.

Entities:  

Mesh:

Year:  1987        PMID: 3815265     DOI: 10.1002/1097-0142(19870301)59:5<1046::aid-cncr2820590533>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  78 in total

Review 1.  Management of sarcomas of the head and neck.

Authors:  Bruce Brockstein
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

Review 2.  Sinonasal tract angiosarcoma: a clinicopathologic and immunophenotypic study of 10 cases with a review of the literature.

Authors:  Brenda L Nelson; Lester D R Thompson
Journal:  Head Neck Pathol       Date:  2007-10-25

3.  Ecchymotic groin plaques in an immunocompromised man.

Authors:  Anatoli Freiman; Khue Nguyen; A Kevin Watters
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

4.  Cutaneous angiosarcoma of the eyelids.

Authors:  R M Conway; T Hammer; A Viestenz; L M Holbach; R M Conway
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

5.  Aneurysmal and haemangiopericytoma-like fibrous histiocytoma.

Authors:  B W Zelger; B G Zelger; H Steiner; D Ofner
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

Review 6.  Pitfalls in the histopathologic diagnosis of pyogenic granuloma.

Authors:  S B Kapadia; D K Heffner
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

Review 7.  Angiosarcomas and taxanes.

Authors:  Nicolas Penel; Amélie Lansiaux; Antoine Adenis
Journal:  Curr Treat Options Oncol       Date:  2007-12-08

8.  Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment.

Authors:  Jong-Hyuk Kim; Aric M Frantz; Katie L Anderson; Ashley J Graef; Milcah C Scott; Sally Robinson; Leslie C Sharkey; Timothy D O Brien; Erin B Dickerson; Jaime F Modiano
Journal:  Exp Cell Res       Date:  2014-02-25       Impact factor: 3.905

9.  Can the clinical course of cancer be influenced by non-antineoplastic drugs?

Authors:  L J Brandes; L A Friesen
Journal:  CMAJ       Date:  1995-09-01       Impact factor: 8.262

10.  Characteristics and Prognosis of Primary Head and Neck Angiosarcomas: A Surveillance, Epidemiology, and End Results Program (SEER) Analysis of 1250 Cases.

Authors:  Kevin C Lee; Sung-Kiang Chuang; Elizabeth M Philipone; Scott M Peters
Journal:  Head Neck Pathol       Date:  2018-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.